EIF2AK4 and neuropathy: Although these studies provide a biochemical mechanism through which tRNA synthetase mutations may act and identify GCN2 as a therapeutic target, they do not directly resolve whether the neuropathy results from the further decrease in protein synthesis that results from phosphorylation of eIF2α, from a toxic effect of ATF4 target-gene expression, or from a combination of these ISR actions.